Endometrial cancer (EC) is the most common malignancy of female genital tract in developed countries [1]. Because of the early onset of symptoms, bleeding, the majority of cases is diagnosed early (80% in stage I) [2] and with the standard surgery of total abdominal hysterectomy and bilateral salpingo-oophorectomy with lymph-node assessment a 5-year survival rate above 95% has been reported [3].

On the other hand, the increasing mean age of the population, the presence of various medical comorbidities and obesity are more and more frequently severe contraindications to standard surgical treatment [45]. In these inoperable women, EC treatment is still a challenge due to the lack of unequivocal management guidelines [6]. Number of therapeutic strategies have been adopted over the years, such as definitive radiation with brachytherapy alone or external beam radiation therapy (EBRT) combined with brachytherapy [7], the use of progestin therapy with high-dose medroxyprogesterone acetate (MPA) or megestrol acetate (MA) limited to pilot studies [8]. More recently, the additional benefit from a weight loss programme associated with metformin and levonorgestrel-releasing intrauterine device (LNG-IUD) was reported [9].

Recently some authors [1101112] adopted conservative therapeutic strategies with encouraging outcomes in women with EC of childbearing age and desiring pregnancies. In postmenopausal conditions, only 1 case was reported [13] about a woman with well differentiated EC that refusing hysterectomy was treated with hysteroscopic endometrial resection and did not present any recurrence at 5 years follow-up.

In this study, we adopted for the first time a new therapeutic strategy consisting of a hysteroscopic endo-myometrial resection of the uterine cavity and the positioning of adjuvant local hormone therapy for the treatment of a group of postmenopausal women with well differentiated EC who presented a high perioperative risk and who refused or were unable to undergo standard radiation therapy.

The women had a mean±standard deviation (SD) age of 69±9 years and BMI of 33±5 kg/m². All were discharged no later than the third of hospitalization with no side-effects and complications. Median duration of hospitalization was 2 days (range, 1–3 days). The women were followed for the first year every 3 to 9 months with diagnostic hysteroscopy with targeted biopsies to verify endometrial features and the correct position of the LNG-IUD, then with TVS and hysteroscopy with biopsies every 6 months up to the third year and annually in the last 2 years. Five (55.6%) women showed a complete response to hormone therapy after 3 months while the others (44.4%) showed a partial response at 3 months and a complete response at 6 months. All of them completed follow-up and none had side effects due to local hormone therapy. Surveillance by TVS and hysteroscopy were negative for recurrences for all women during the entire follow-up. None of the women complained abnormal uterine bleeding. The LNG-IUD was replaced at the end of follow-up and currently 7 women (77.8%) are examined annually with TVS while 2 women (22.2%) died from their comorbidity. One died of pancreatic cancer after 2 more years without signs of recurrence in uterine histology. Another woman died of chronic renal failure unrelated to the EC.

Despite today's advances in surgical techniques, anesthesiology and perioperative management, a significant fraction (10%) of women newly diagnosed with EC is unable to undergo standard surgery not only for age but also for their own medical comorbidities such as high BMI, cardiovascular disease, obesity-hypoventilation syndrome, and diabetes-related organ damage [416]. Frequent perioperative complications are obstructive sleep apnea, arrhythmias, acute cardiac events, and venous thrombotic events. Therefore, these women require more detailed preoperative evaluation and postoperative intensive care according to Royal College of Obstetricians and Gynaecologists [17]. In such cases, a benefit-risk assessment of surgery may lead to an individualized decision to perform a non-standard surgery or a limited staging procedure. Alternatively, these cases can still be managed surgically by vaginal hysterectomy, definitive radiation therapy, combining EBRT and brachytherapy, or hormonal treatment [3].

EC is radiosensitive, and radiotherapy can be used as the sole treatment modality. Radiotherapy in surgically inoperable women reported 5-year survival rate of 87% for cases with stage I [18], although recurrence rates are 18% in obese women [16]. Furthermore, radiotherapy is often not applicable, especially in obese women, due to material and technical reasons and dosimetric difficulties [6].

Regarding the use of oral progestin in EC, few studies conducted on younger women wishing to preserve fertility reported a response rate of 50% to 70% in women treated with high-dose progesterone as primary therapy, but a remarkable rate of recurrence (>25%) was observed [8]. LNG-IUD has also been used as part of a fertility-sparing regimen for both precancerous and grade 1 EC [19]. MPA, MA, and LNG-IUD are the progestins most commonly used; nevertheless, the doses and duration of the treatment are not yet standardized [20]. Some studies also reported the use of LNG-IUD in selected cases of inoperable EC with contradictory outcomes, histologic regression from 25% [21] to 75% [22] after 6/12 months therapy. A recent meta-analysis [23] did not take a definitive position in the non-operable EC conservative management as there are no randomised controlled trials on the use of this therapy.

Since there is no standardized treatment in EC cases with surgical high risk, several authors have tried alternative treatments. Laframboise et al. [6] described a case of a woman with EC of 49 years medically severely compromised treated with a complete hysteroscopic resection and high-dose-rate intracavitary radiation. Hawkes et al. [9] investigated the effectiveness of LNG-IUD with or without metformin and with or without weight loss in obese women with early stage EC. They did not find a better outcome than standard treatment but demonstrated reduction in health system costs and lower incidence of adverse events. Vilos et al. [13] reported a case of a 54-year-old woman with well-differentiated EC and superficial myometrial invasion that strongly refused hormonal therapy and standard surgery without surgical contraindications. She was treated only with hysteroscopic resection and showed no recurrence after 5 years follow-up.

In this pilot study, we reported for the first time a case series on hysteroscopic treatment combined with hormonal therapy in a group of 9 women with primary EC with or without minimal myometrial invasion at high surgical risk with standard surgical treatment. This treatment is based on the favorable prognosis of grade 1 mini-invasive tumors and on the fact that no residual cancer was found in post-hysterectomy specimens after incidental diagnosis of EC by hysteroscopic resection [24]. In spite of limitations of case series, we demonstrated that hysteroscopic resection is a safe and effective procedure in these women since none of them had acute or delayed complications, the lesions were completely removed and the margins were disease-free in all cases. Women were extensively counselled about pros and cons of different treatments (radiotherapy/progesterone therapy), lack of data, risk of recurrence and need for close follow up. The outcomes we have had supported our view. Currently 7 women are negative for recurrence after 5-year follow up. Two women died of unrelated cancer diseases. Therefore, we believe that the hysteroscopic resection is the best procedure to evaluate tumor extension and status of endometrium. It provides with certainty of tumor staging and involvement of the myometrium and allows an optimal cytoreduction facilitating the therapeutic effect of progestin. This procedure is safe and effective if performed by surgeons experienced in minimally invasive techniques. Our preliminary outcomes are comparable to those of radiotherapy but with a lower or absent complication rate [18].

Concerning to the increased risk of cell dissemination within the peritoneal cavity after hysteroscopic procedure, several studies demonstrated that a positive peritoneal cytology does not modify the prognosis of the disease [25]. Other authors [2627] observed that the clinical significance of positive peritoneal cytology could reflect other adverse prognostic factors (i.e. high-risk EC or presence of other metastases) and that positive peritoneal cytology did not influence survival in case of stage I EC.

Despite limited number of cases and short follow-up, we can advance the hypothesis that hysteroscopic resection and LNG-IUD therapy can be considered an effective alternative to traditional treatment for women at high surgical risk with stage IA EC. Further evaluation is needed before using this procedure in the routine practice, and prospective, and multicenter studies with a longer follow-up are requested to validate this therapeutic option.